Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $24.25.

A number of research firms recently weighed in on ARCT. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 9th.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. boosted its stake in Arcturus Therapeutics by 12.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after acquiring an additional 262,347 shares during the last quarter. Amova Asset Management Americas Inc. grew its position in shares of Arcturus Therapeutics by 12.9% during the 1st quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,648,000 after acquiring an additional 262,347 shares during the period. Heartland Advisors Inc. purchased a new stake in shares of Arcturus Therapeutics during the 1st quarter worth approximately $1,976,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of Arcturus Therapeutics by 23.8% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 346,207 shares of the biotechnology company’s stock worth $2,327,000 after purchasing an additional 66,528 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Arcturus Therapeutics in the 1st quarter worth approximately $116,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $8.23 on Monday. The company has a fifty day simple moving average of $6.77 and a 200 day simple moving average of $7.40. Arcturus Therapeutics has a 12-month low of $5.50 and a 12-month high of $24.17. The company has a market cap of $233.90 million, a P/E ratio of -2.49 and a beta of 2.39.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The firm had revenue of $2.96 million for the quarter, compared to the consensus estimate of $3.11 million. Sell-side analysts predict that Arcturus Therapeutics will post -3.48 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.